India launched Nafithromycin, its first indigenous Macrolide antibiotic, developed by Wockhardt with BIRAC support. Marketed as ‘Miqnaf,’ it treats drug-resistant pneumonia with a three-day course and tenfold efficacy, marking the first global breakthrough in its class in over 30 years.
Click to View MoreIndia’s biotechnology industry has grown rapidly, expanding from a small startup base in 2014 to over 10,000 firms by 2025 and reaching a bioeconomy value of USD 165.7 billion. Supported by initiatives like BIRAC, DBT, and the BioE3 Policy, the sector drives innovation in vaccines, genomics, and bio-manufacturing. However, it faces challenges such as funding shortages, fragmented infrastructure, and outdated regulations. With strategic reforms, investment in R&D, and global partnerships, India aims to achieve a USD 300 billion bioeconomy by 2030 and emerge as a global leader in biotechnology.
Click to View MoreE-waste, the fastest-growing solid waste stream globally, is now one of India’s most pressing yet least acknowledged urban crises. Our embrace of electronics has outpaced our ability to manage their afterlife, resulting in widespread informal recycling practices that are endangering both ecosystems and human health—especially in the country’s most marginalised communities.
Click to View MoreIndia’s Carlsberg Ridge licence makes it a deep-sea pioneer, securing critical minerals for energy transition and asserting strategic autonomy in the Indo-Pacific; amid environmental risks and Sino-Indian rivalry, success depends on ISA reforms, green technology, and sustainability-focused policies.
Click to View MoreThe AI for Viksit Bharat Roadmap reimagines AI as India’s growth engine, enabling equitable prosperity through infrastructure, skilling, and governance. By bridging growth gaps and creating transformative jobs, India can spearhead responsible global AI leadership, realizing Viksit Bharat by 2047.
Click to View More
© 2025 iasgyan. All right reserved